Cassava Sciences Q3 2024 Earnings Report $2.55 -0.11 (-4.14%) (As of 12/17/2024 05:56 PM ET) Earnings HistoryForecast Cassava Sciences EPS ResultsActual EPS-$0.58Consensus EPS -$1.37Beat/MissBeat by +$0.79One Year Ago EPS-$0.61Cassava Sciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACassava Sciences Announcement DetailsQuarterQ3 2024Date11/7/2024TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptSAVA Earnings History This Crypto Is Set to Explode in December (Ad)Discover our #1 crypto for the Trump Presidency Bull Run now! (Available for a Short Time) We highly recommend this hot altcoin before prices get too high Check it out by going here now Cassava Sciences Earnings HeadlinesCASSAVA SCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVADecember 17 at 10:52 PM | globenewswire.comCASSAVA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Cassava Sciences, Inc and Encourages Investors to Contact the FirmDecember 17 at 9:00 PM | globenewswire.comDeFi Coin on Verge of Breakout![FREE BOOK] Can You Make a Fortune in Crypto with $50? Get started now before the market takes off! December 18, 2024 | Crypto 101 Media (Ad)ROSEN, A LONGSTANDING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAVADecember 17 at 8:21 PM | globenewswire.comSAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitDecember 17 at 4:00 PM | prnewswire.comLevi & Korsinsky Notifies Cassava Sciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - SAVADecember 17 at 5:45 AM | prnewswire.comSee More Cassava Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cassava Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cassava Sciences and other key companies, straight to your email. Email Address About Cassava SciencesCassava Sciences (NASDAQ:SAVA), a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.View Cassava Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Cintas (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
